NCT05269810View on ClinicalTrials.gov

Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

February 25, 2022

Study Completion Date

March 21, 2022

Conditions
Primary Sjögren's Syndrome (pSS)
Interventions
DRUG

SA001 Low dose

3 tablets b.i.d for 8 weeks

DRUG

SA001 Mid dose

3 tablets b.i.d for 8 weeks

DRUG

SA001 High dose

3 tablets b.i.d for 8 weeks

DRUG

Placebo

3 tablets b.i.d for 8 weeks

Trial Locations (1)

03722

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

NCT05269810 - Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter